CRSP (CRISPR Therapeutics AG) Other Operating Expense : $-2.8 Mil (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Other Operating Expense?

CRISPR Therapeutics AG's Other Operating Expense for the three months ended in Sep. 2024 was $-0.6 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.8 Mil.

CRISPR Therapeutics AG's quarterly Other Operating Expense declined from Mar. 2024 ($-0.5 Mil) to Jun. 2024 ($-0.5 Mil) and declined from Jun. 2024 ($-0.5 Mil) to Sep. 2024 ($-0.6 Mil).

CRISPR Therapeutics AG's annual Other Operating Expense increased from Dec. 2021 ($-1.9 Mil) to Dec. 2022 ($-0.8 Mil) but then declined from Dec. 2022 ($-0.8 Mil) to Dec. 2023 ($-1.2 Mil).

CRISPR Therapeutics AG Other Operating Expense Historical Data

The historical data trend for CRISPR Therapeutics AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Other Operating Expense Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-0.18

-1.88

-0.76

-1.21

CRISPR Therapeutics AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Operating Expense	Get a 7-Day Free Trial															-	-1.21	-0.50	-0.52	-0.60

CRISPR Therapeutics AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.8 Mil.

CRISPR Therapeutics AG Other Operating Expense Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Executives

Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104